Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Juana Martinez, Michelle Becker, Megan Metzger, Nagma Shah, Erin Garbes Feliciano, Alberto Busmail Haylock, Navin Bhatt, Nikolaos Spyrou, John O. Mascarenhas, Douglas Tremblay, Jonathan Feld, Marina Kremyanskaya, Michal Bar-Natan, Hannah Levavi

Blood (2024) 144 (Supplement 1): 2798.

https://doi.org/10.1182/blood-2024-212243

Published: 2024

Journal Articles

Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)

Marina Kremyanskaya, Ronald Hoffman, Lee Ping Chew, Azizan Sharif, Boyan Semov, Ahlam Naila Kori, Hanlon Sia, Carolyn S. Grove, Ashley P Ng, Akash Kalro, Indu Raman, Ganesh Kasinathan, Olubunmi Oduwole, Monica Gomez-Palou, Henry Fok, Steve Romano, Curtis Rambaran, Alberto Martinez

Blood (2024) 144 (Supplement 1): 656.

https://doi.org/10.1182/blood-2024-205854

Published: 2024

Journal Articles

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Aaron T. Gerds, Andrew T. Kuykendall, Marina Kremyanskaya, Ellen K. Ritchie, Jason Gotlib, Jeanne Palmer, Kristen M. Pettit, Victor Priego, Uttam Kumar Nath, Abdulraheem Yacoub, Arkapal Bandyopadhyay, Suneel Gupta, Sarita Khanna, Arturo Molina, Naveen Pemmaraju

Blood (2024) 144 (Supplement 1): 4559.

https://doi.org/10.1182/blood-2024-197985

Published: 2024

Journal Articles

A Novel Three-Way Translocation Involving ETV6-IL3 Drives AML with Eosinophilia

Ariel Siegel, Joseph Tripodi, Brianna Kelly, Sebastian Elghaity-Beckley, Michelle Becker, Douglas Tremblay, Jonathan Feld, Hannah Levavi, Marina Kremyanskaya, Bridget Kelly Marcellino, Christian Salib, Alla Keyzner, Amy Duffield, John O. Mascarenhas, Vesna Najfeld, Alan Shih

Blood (2024) 144 (Supplement 1): 6098.

https://doi.org/10.1182/blood-2024-203588

Published: 2024

Journal Articles

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 243.

https://doi.org/10.1182/blood-2024-206688

Published: 2024

Journal Articles

Acute Promyelocytic Leukemia in the Molecular Age

Navin Bhatt, Michelle Becker, Juana Martinez, Hannah Levavi, Kyle Farina, Marina Kremyanskaya, Bridget Kelly Marcellino, Alan Shih, Lewis R. Silverman, Vesna Najfeld, John O. Mascarenhas, Douglas Tremblay, Jonathan Feld

Blood (2024) 144 (Supplement 1): 6131.

https://doi.org/10.1182/blood-2024-211957

Published: 2024

Journal Articles

Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?

Hannah Goulart, Dahniel L Sastow, Nicholas Dreher, Metodi Balev, Grace Van Hyfte, Marina Kremyanskaya, Ronald Hoffman, John Mascarenhas, Douglas Tremblay

Blood (2023) 142 (Supplement 1): 3200.

https://doi.org/10.1182/blood-2023-182450

Published: 2023

Journal Articles

Conventional Cytogenetic Analysis and Array CGH+SNP Identify Essential Thrombocythemia (ET)/Prefibrotic Primary Myelofibrosis (pre-PMF) Patients Who Are at Risk for Disease Progression

Joseph Tripodi, Ronald Hoffman, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Ian Novoselac, Vesna Najfeld

Blood (2023) 142 (Supplement 1): 1832.

https://doi.org/10.1182/blood-2023-181092

Published: 2023

Journal Articles

Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study

Ellen K. Ritchie, Kristen Marie Pettit, Andrew T. Kuykendall, Marina Kremyanskaya, Naveen Pemmaraju, Sarita Khanna, Arturo Molina, Suneel Gupta

Blood (2023) 142 (Supplement 1): 745.

https://doi.org/10.1182/blood-2023-178253

Published: 2023

Journal Articles

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis

Blood (2023) 142 (Supplement 1): 321.

https://doi.org/10.1182/blood-2023-181795

Published: 2023

Journal Articles

Array CGH + SNP in ALL Enhances Detection of Complex Cytogenetic Profiles and Suggests That PRSS1 Loss May Play a Role in Leukemogenesis

Hannah Levavi, Daiva Ahire, Yosef Joseph Rene Amel Riazat-Kesh, Tianxiang Sheng, Dahniel L Sastow, Jonathan Feld, Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas, Vesna Najfeld, Michal Bar-Natan

Blood (2023) 142 (Supplement 1): 6062.

https://doi.org/10.1182/blood-2023-185332

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Ganesh Sivakumar, Shivani Handa, Andrew Srisuwananukorn, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Yelena Ginzburg, Xiaoli Wang, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2023-178822

Published: 2023

Journal Articles

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba, Amir T. Fathi, Ghayas C. Issa, Jessica K. Altman, Pau Montesinos, Mrinal M. Patnaik, James M. Foran, Stephane De Botton, Maria R. Baer, Gary J. Schiller, Roland B. Walter, Marina Kremyanskaya, Kristen M. Pettit, Stephen A Strickland, Blake Tomkinson, Marilyn Tabachri, Mollie Leoni, Stephen Dale, Eunice S. Wang

Blood (2022) 140 (Supplement 1): 153–156.

https://doi.org/10.1182/blood-2022-167412

Published: 2022

Journal Articles

Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

Metodi Balev, Nicole Zubizarreta, Erin Bresnahan, Jonathan Feld, Marina Kremyanskaya, Alla Keyzner, Alan H. Shih, Bridget K Marcellino, Lewis R. Silverman, Michal Bar-Natan, John Mascarenhas, Douglas Tremblay

Blood (2022) 140 (Supplement 1): 139–140.

https://doi.org/10.1182/blood-2022-167828

Published: 2022

Journal Articles

Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Michal Bar-Natan, John Mascarenhas, Aaron T. Gerds, Ruben Mesa, Vikas Gupta, Marina Kremyanskaya, Mikaela Dougherty, Frank Fabris, Kathryn Johnson, Ashley Yu, Heidi E. Kosiorek, Carolyn Mead-Harvey, Amylou C. Dueck, Ronald Hoffman, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 3988–3990.

https://doi.org/10.1182/blood-2022-164678

Published: 2022

Journal Articles

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice Wang, Aaron T. Gerds, Gabriela S. Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen T Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2022) 140 (Supplement 1): 579–582.

https://doi.org/10.1182/blood-2022-160384

Published: 2022

Journal Articles

Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy

Ruben Mesa, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Claire Harrison, Raajit K. Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Gozde Colak, Debarshi Dey, John Mascarenhas

Blood (2022) 140 (Supplement 1): 11056–11059.

https://doi.org/10.1182/blood-2022-159389

Published: 2022

Journal Articles

Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera

Naveen Pemmaraju, Srdan Verstovsek, Marina Kremyanskaya, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 6835–6837.

https://doi.org/10.1182/blood-2022-163742

Published: 2022

Journal Articles

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Raajit K Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Qing Li, Sandra Klein, Claire Harrison

Blood (2022) 140 (Supplement 1): 586–589.

https://doi.org/10.1182/blood-2022-158147

Published: 2022

Journal Articles

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

Claire Harrison, Marina Kremyanskaya, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Soumik Dutta, John Mascarenhas

Blood (2022) 140 (Supplement 1): 9659–9662.

https://doi.org/10.1182/blood-2022-157735

Published: 2022

NARROW

Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

A Novel Three-Way Translocation Involving ETV6-IL3 Drives AML with Eosinophilia

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Acute Promyelocytic Leukemia in the Molecular Age

Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?

Conventional Cytogenetic Analysis and Array CGH+SNP Identify Essential Thrombocythemia (ET)/Prefibrotic Primary Myelofibrosis (pre-PMF) Patients Who Are at Risk for Disease Progression

Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis

Array CGH + SNP in ALL Enhances Detection of Complex Cytogenetic Profiles and Suggests That PRSS1 Loss May Play a Role in Leukemogenesis

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy

Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only